Ascendis Pharma ASND NASDAQ · Healthcare · Denmark
$267.07 +3.00% +$7.79
Summary
71 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 72 EUR is left as net profit.
- Revenue grew by 138% a year over the last 3 years.
- It earns 43 EUR a year on every 100 EUR of invested capital.
- It holds more cash than debt: 811.9M € against 449.9M €.
What to watch
- Operating profit does not even cover the interest on its debt.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 20.3 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 151% a year over 5 years. Over the last 3 years it grew by 138% a year. For the next fiscal year analysts expect revenue to grow by 97%.
Growth in detailDoes it make money?
Very wellWhere 100 EUR of revenue goes
- Cost of sales 9.8 EUR
- Research and development 26 EUR
- Sales and administration 54 EUR
- Taxes and other -61 EUR
- Net profit 72 EUR
Net profit, industry median (Biotechnology) -10 EUR
Out of every 100 EUR of revenue, 72 EUR is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.3 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 24
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $311.17 is 17% above today's price. 92% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- Europe 90%
- DENMARK 9.6%
Europe brings in 90% of revenue.
Segments in detail